Table 3. Treatments and management characteristics of patients with MAS.

No.	Age/sex	Disease	Disease duration (months)	1st Treatment (corticosteroids)	2nd Treatment	3rd Treatment	Combined infection	Alive/dead
1	19/F	SLE	1	1 mg/kg	IVIG + PP	TCZ, RTX	Bacteremia	Dead
2	20/M	SLE	0	1 mg/kg	-	-	-	Alive
3	20/F	AOSD	1	1 mg/kg	VP16	-	-	Alive
4	22/F	SLE	1	100 mg	IVIG + PP	-	Pneumonia	Dead
5	22/F	AOSD	0	500 mg	IVIG	-	-	Alive
6	23/F	SLE	182	1 mg/kg	-	-	-	Alive
7	23/F	SLE	41	1 mg/kg	-	-	-	Alive
8	30/F	SLE	146	1 mg/kg	IVIG	CsA	-	Alive
9	32/F	SLE	127	1 mg/kg	IVIG + PP	CsA, TCZ	Pneumonia	Alive
10	35/F	AOSD	0	1 mg/kg	CsA	-	Viral infection	Alive
11	37/F	SLE	65	1 mg/kg	CsA, VP16	-	Bacteremia	Alive
12	38/F	SLE	0	1 mg/kg	IVIG + PP	RTX	-	Dead
13	40/F	AOSD	0	0.5 mg/kg	CsA	-	-	Alive
14	43/F	SLE	60	1 mg/kg	IVIG + PP	TCZ, RTX, CsA, VP16, IFX	PCP, Viral infection	Dead
15	49/F	SLE	0	1 mg/kg	CYC	-	Bacteremia	Alive
16	51/F	AOSD	0	1 mg/kg	-	-	-	Alive
17	57/F	SLE	0	1 mg/kg	IVIG + PP	CsA, VP16	Fungal infection	Dead
18	61/F	SLE	2	1 mg/kg	IVIG + PP	TCZ	-	Dead
19	68/F	SLE	2	1 mg/kg	IVIG + PP	CsA	Fungal infection	Alive
20	70/M	AOSD	0	1 mg/kg	IVIG + PP	CsA, VP16	Fungal infection	Dead

SLE: Systemic lupus erythematosus, IVIG: Intravenous immunoglobulin, PP: Plasmapheresis, TCZ: Tocilizumab, RTX: Rituximab, AOSD: Adult-onset still’s disease, VP16: Etoposide, PCP: Pneumocystis pneumonia, CsA: Cyclosporin, IFX: Infliximab